Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

NCT04981899 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.

NCT NCT04981899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04981899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Lead sponsor
St. Petersburg State Pavlov Medical University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 1, 2021
Completion date
September 15, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma